Compare Entegris Inc (ENTG) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Stryker Corporation — how do they compare? Entegris Inc trades at $165.38 (market cap $24.78B), while Stryker Corporation trades at $277.3 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 4.3× Entegris Inc's market cap, and Stryker Corporation pays the higher dividend (1.27%). Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Stryker Corporation for 21 Days on average.
| ENTG | SYK | |
|---|---|---|
Market Cap | $24.78B | $106.24B |
Volume | 2,648,320 | 2,982,001 |
Sector | Technology | Health |
52-Week High | $184.00 | $388.35 |
52-Week Low | $68.80 | $269.75 |
Typical Hold Time | 41 Days | 21 Days |
Enterprise Value | $27.99B | $117.70B |
Dividend Yield | 0.25% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $164.22, down 1.26% on the day, with a bullish technical signal from moving averages and strong institutional interest. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results expected soon. Revenue remains stable around $3.2B, while profitability metrics show a net income margin of 9.18%. Analysts maintain a strong buy consensus with a $182.43 price target, indicating potential upside.
The outlook for ENTG is positive, driven by AI-related semiconductor demand and operational improvements. Key risks include high valuation multiples and exposure to semiconductor cycle volatility. Institutional accumulation and recent patent defenses support confidence, but investors should monitor execution against earnings expectations and industry capital spending trends.
Stryker (SYK) trades at $277.52, up 0.77% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279. Fundamentally, the company reported strong profitability with a 14.43% net income margin in 2026 and beat EPS estimates in two of the last three quarters. However, recent news highlights potential legal and manufacturing issues that have pressured investor sentiment.
The outlook is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities lie in SYK's robust earnings growth and market leadership in medical technology, but risks include ongoing legal investigations and persistent manufacturing challenges that could impact future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
